A mitochondrial heteroplasmy percentage is a measurement from a particular specimen, not a whole-body disease score. Its interpretation depends on the variant, sampled tissue and analytical method. For researchers comparing participants or following change over time, those details belong beside the percentage rather than in supplementary notes. UK laboratory guidance explicitly places heteroplasmy interpretation within its tissue context. UK mitochondrial testing guidelines.
What heteroplasmy measures
Mitochondria help convert energy from food into ATP, a molecule cells use to power their activities. They contain their own small genome, mitochondrial DNA, or mtDNA. Its 37 genes contribute to mitochondrial function, including energy production and the machinery needed to assemble proteins. Most human DNA, however, sits in the cell nucleus. MedlinePlus: mitochondrial DNA.
Cells contain multiple mtDNA copies. Heteroplasmy means that different mtDNA sequences coexist; a reported percentage describes the proportion carrying a specified variant in the material examined. Homoplasmy describes a variant present in all copies. Neither term, by itself, establishes whether the sequence change causes disease. UK mitochondrial testing guidelines.
This distinction changes the research question. Measuring how much of a variant is present and establishing what that variant does are separate tasks. A precise measurement cannot substitute for evidence that the variant is relevant to the phenotype.
Why specimen choice changes the answer
Heteroplasmy can differ between tissues and change within a tissue over time. The pathogenic MT-TL1 variant m.3243A>G provides an important example: its level in blood can decline with age. Some other pathogenic changes, including certain large mtDNA deletions, may be detectable only in muscle. A blood result therefore cannot automatically represent another organ. UK mitochondrial testing guidelines.
NHS educational guidance describes testing additional tissues when clinical suspicion remains strong after uninformative blood testing. Depending on the question, laboratories may examine muscle or urinary epithelial cells, among other specimens. This is a specialist diagnostic decision; it does not mean every research participant needs an invasive biopsy. NHS mitochondrial DNA testing overview.
For study design, the practical implication is to avoid silently pooling unlike measurements. Record the specimen and collection age, and explain how tissue differences enter the analysis. If one group contributes blood and another contributes muscle, a difference in percentages needs investigation before it is interpreted as a biological difference between groups.
Detection and quantification need separate scrutiny
Targeted testing asks about selected variants. Sequencing the mitochondrial genome examines a broader range of changes, and dedicated sequencing approaches can identify low-level heteroplasmy. Nevertheless, absence from a tested tissue does not exclude a mitochondrial condition. Nuclear DNA variants can also cause primary mitochondrial disease. NHS testing methods and limitations.
A useful research worksheet asks three questions:
- What was measured? Record the exact variant, tissue, collection age and reported percentage.
- What could the assay resolve? Record its validated detection and quantification limits, coverage and relevant exclusions.
- What conclusion is justified? Separate variant detection, evidence of pathogenicity and association with the measured clinical outcome.
This worksheet is a reporting aid, not a diagnostic algorithm. It makes missing information visible and helps collaborators identify whether apparently conflicting results actually address the same question.
A threshold is not a universal clinical cutoff
For heteroplasmic pathogenic variants, dysfunction can emerge when the variant proportion exceeds a tissue-level threshold. That threshold differs by variant. Consequently, a single percentage should not be used as a universal boundary between health and disease. UK mitochondrial testing guidelines.
The broader biology also remains incompletely understood. MedlinePlus describes unresolved questions about why particular mtDNA changes affect specific organs and why related changes produce different clinical features. A molecular measurement may therefore be informative without providing an individual prognosis. MedlinePlus disease mechanisms and uncertainties.
Keep research interpretation distinct from established care
Dedicated mtDNA testing already has an established diagnostic role. An exploratory association between heteroplasmy and an outcome answers a different question: whether a measurement tracks that outcome in the studied setting. Researchers should state whether they are evaluating detection, diagnosis, prognosis or treatment response, rather than treating these as interchangeable achievements.
A proposed biomarker needs evidence suited to its intended use. Until that evidence exists, report the sampled tissue, method and uncertainty alongside the finding, and keep any claim about clinical decisions within the scope actually evaluated.